Brentuximab Vedotin + Lenalidomide + Rituximab for Diffuse Large B-Cell Lymphoma

(ECHELON-3 Trial)

Recruiting in Palo Alto (17 mi)

+8 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 3

Waitlist Available

Sponsor: Seagen, a wholly owned subsidiary of Pfizer

No Placebo Group

Pivotal Trial (Near Approval)

Prior Safety Data

Breakthrough Therapy

Trial Summary

What is the purpose of this trial?

Participants in this study will have diffuse large B-cell lymphoma (DLBCL) that has come back or not gotten better with treatment. The trial will study whether brentuximab vedotin plus two drugs works better to treat this type of cancer than the two drugs alone. Participants will be randomly assigned to get either brentuximab vedotin or placebo. The placebo will look like brentuximab vedotin, but has no medicine in it. Since the study is "blinded," participants and their doctors will not know whether a participant gets brentuximab vedotin or placebo. All participants in the study will get rituximab and lenalidomide. These are drugs that can be used to treat DLBCL.

Research Team

Pfizer Ct.gov Call Center

Principal Investigator

Pfizer

Eligibility Criteria

Inclusion Criteria

You have been diagnosed with diffuse large B-cell lymphoma (DLBCL).

You don't have damage to the nerves in your arms or legs.

You have been treated for DLBCL with at least two different types of medication.

Exclusion Criteria

I'm sorry, it seems like you did not provide a criterion for me to rewrite. Can you please provide one?

I'm sorry, it seems like the criterion is missing. Can you please provide more information?

I'm sorry, I see no criterion listed. Please provide additional information.

Treatment Details

Interventions

• Brentuximab Vedotin (Monoclonal Antibodies)
• Lenalidomide (Other)
• Placebo (Other)
• Rituximab (Monoclonal Antibodies)

Participant Groups

Group I: Experimental Arm Experimental Treatment 3 Interventions

Brentuximab vedotin + lenalidomide + rituximab

Group II: Control Arm Active Control 3 Interventions

Placebo + lenalidomide + rituximab

Find a Clinic Near You

Research Locations Nearby Select from list below to view details:

New York Cancer and Blood Specialists Shirley, NY

Saint Louis University Saint Louis, MO

Henry Ford Health System Detroit, MI

Alabama Oncology Birmingham, AL

More Trial Locations

Who Is Running the Clinical Trial?

Seagen, a wholly owned subsidiary of Pfizer

Lead Sponsor

Trials

20

Patients Recruited

4,900+

Seagen Inc.

Lead Sponsor

Trials

212

Patients Recruited

73,800+

Founded

1997

Headquarters

Bothell, USA

Known For

Antibody-Drug Conjugates

Top Products

Adcetris (brentuximab vedotin), Tukysa (tucatinib), Padcev (enfortumab vedotin-ejfv), Tivdak (tisotumab vedotin-tftv)